I guess it depends how specifically you catergorise a class. If your catergory is CAR-T for GBM or GI cancers, CHM is unlikely to be first-in-class.
My point was that there are a large number of CAR-T and other cell therapies currently in development, many further advanced, for treatment of solid tumours including GBM and GI cancers.
For some reason CHM amd IMU forum posts often assert that their trials are the first (or with IMU, will be) to show evidence of CAR-T efficacy in solid tumours. But that's wildly inaccurate.
I guess it depends how specifically you catergorise a class. If...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $46.50K | 11.62M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2565728 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.25pm 19/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |